October 2023 in “Naunyn-Schmiedeberg's Archives of Pharmacology” Custom software found that common allergy drugs might have new uses for various conditions and could improve survival in some cancers.
December 2021 in “Vestnik Rossiĭskoĭ akademii meditsinskikh nauk / Rossiĭskaia akademiia meditsinskikh nauk” Personalized vitamin and trace element treatment improves hair density and reduces hair loss in men with early-stage androgenic alopecia.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” JAK inhibitors offer new hope for treating severe alopecia areata.
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
84 citations
,
July 2003 in “European journal of biochemistry” Mouse skin can produce and process serotonin, with variations depending on hair cycle, body location, and mouse strain.
13 citations
,
December 2017 in “Archives of Medical Sciences” Rivaroxaban can cause liver injury, allergic reactions, blood vessel inflammation, and hair loss, but these side effects are rare.
8 citations
,
May 2017 in “Chinese Journal of Integrative Medicine” Miscanthus sinensis flower extract may help promote hair growth and prevent hair loss.
The new microneedle system improves hair growth in alopecia treatment.
Hair follicles can be used to quickly assess drug effects in cancer treatment.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
1 citations
,
October 2025 in “International Journal of Dermatology” Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.
10 citations
,
July 1994 in “Journal of Dermatological Science” Cyclosporin extends hair growth in mice, but high-dose corticosteroids block this effect.
January 2026 in “International Journal of Innovative Technologies in Social Science” JAK inhibitors show promise for treating alopecia areata, but more research is needed.
8 citations
,
July 2024 in “Children” Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.
7 citations
,
March 2023 in “Antioxidants” Rosemary may help treat various skin conditions due to its antioxidant and anti-inflammatory properties.
4 citations
,
October 2021 in “Canadian Journal of Physiology and Pharmacology” Women with pancreatic cancer are more likely to have certain side effects from chemotherapy than men.
February 2026 in “International Journal of Molecular Sciences” Extracellular vesicles show promise for medical use but face challenges in standardization and safety.
3 citations
,
September 2024 in “Dermatology and Therapy” Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
1 citations
,
July 2024 in “PharmacoEconomics - Open” The EQ-5D-5L tool may not accurately measure the impact of alopecia areata on patients' lives.
April 2025 in “Dermatology and Therapy” Significant, lasting hair regrowth is needed to improve how patients with Alopecia Areata feel about their condition.
January 2025 in “Repository of the Academy's Library (Library of the Hungarian Academy of Sciences)” Baricitinib is effective and safe for treating severe alopecia areata.
2 citations
,
January 2023 in “Prague Medical Report” JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
67 citations
,
February 2015 in “Life Sciences” Some plant-based treatments can help with benign prostatic hyperplasia symptoms, but more research is needed to confirm their safety and effectiveness.